The METTL3/SLC2A1-DT/β-catenin axis is crucial for glycolysis and HCC tumorigenesis, and targeting this pathway may act as a possible treatment option for HCC patients. This evidence concerns the gene SLC2A1 and hepatocellular carcinoma.